Glargine insulin

ApprovedSmall molecule

AstraZeneca

Glargine insulin is one of 128 small molecule programs targeting Coronary Artery Bypass. It is currently in Approved.

Indications

Total Trials

Active Trials

127

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery BypassActive, not recruiting

HyperglycemiaActive, not recruiting

Type 2 DiabetesActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Coronary Artery BypassPhase 3

Active, not recruiting

HyperglycemiaApproved

Active, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Glargine insulin

AstraZeneca

Approved

2 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

Aurlumyn

BBTG International Inc.

Preclinical

1 5

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 6

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 7

Sulfonylureas

Eli Lilly

Preclinical

1 8

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 9

GLP-1

RRigshospitalet, Denmark

Preclinical

1 10

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02551874·650 enrolled

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

Completed·JJoslin Diabetes Center·Phase 4·NCT00353834·72 enrolled

MPA2 trials

Insulin Therapy in the Hospital Comparing Two Protocols

Completed·CCook County Health·Phase 4·NCT00841919·60 enrolled

Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital

Completed·UUniversity of Colorado, Denver·Phase 4·NCT01203774·43 enrolled

Parenteral Nutrition2 trials

Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)

Completed·KKing Faisal Specialist Hospital & Research Center·Phase 4·NCT02216799·61 enrolled

Insulin in Total Parenteral Nutrition

Completed·FFundación Pública Andaluza Progreso y Salud·Phase 4·NCT02706119·163 enrolled

Chronic Kidney Disease1 trial

Glargine Versus NPH in Patients With Chronic Kidney Disease

Completed·UUniversity of Sao Paulo General Hospital·Phase 4·NCT02451917·34 enrolled

Hyperglycemia1 trial

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients

Completed·—·Phase 4·NCT01810952·37 enrolled

3 more indications

Diabetes1 trial

Lunch Time Insulin Injection by School Nurse for Poorly Controlled Diabetes

Completed·—·Phase 4·NCT00340613·36 enrolled

Coronary Artery Bypass1 trial

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients

Completed·EEmory University·Phase 3·NCT01792830·175 enrolled

Unspecified1 trial

Insulin Glargine Vs Standard Insulin Therapy

Completed·UUniversity of Minnesota·Phase 3·NCT00222521·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Glargine insulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glargine insulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glargine insulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Glargine insulin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes2 trials

MPA2 trials

Parenteral Nutrition2 trials

Chronic Kidney Disease1 trial

Hyperglycemia1 trial

Diabetes1 trial

Coronary Artery Bypass1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News